GSK nixed on Advair application

Analysts were surprised to hear that GlaxoSmithKline was handed a "not approvable" letter for the supplemental drug application for the 500/50 strength of Advair Diskus for patients with chronic obstructive pulmonary disease. The company expressed surprise as well.

"The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing recommendations," says the company's statement. "GSK will be meeting with FDA to discuss this request in more detail and determine next steps, including discussion of data GSK has recently generated on the reduction of exacerbations with the Advair 250/50 strength."

- check out the release on the rejection

Related Articles:
Advair fails to hit goal in COPD trial. Report
New research highlights dangers of bronchodilators. Report

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.